Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY3009806

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Vascular endothelial growth factor receptor 2 (VEGFR2) is an attractive therapeutic target in solid malignancies due to its… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2018
2018
TPS538Background: Ramucirumab (RAM), a human IgG1 mAb, inhibits ligand activation of VEGFR2. In REACH, while improvement in… Expand
Is this relevant?
Review
2016
Review
2016
ABSTRACT Introduction: Ramucirumab (IMC-1121B, LY3009806) is a fully humanized monoclonal antibody that targets the extracellular… Expand
Is this relevant?
Review
2016
Review
2016
Angiogenesis is a multistep process that plays a key role in cancer growth and metastases. It is mediated through multiple… Expand
  • figure 1
  • table 1
  • table 2
Is this relevant?
Review
2016
Review
2016
Ramucirumab (IMC-1121B, LY3009806) is a fully human G1 monoclonal antibody that specifically targets vascular endotelial growth… Expand
Is this relevant?
2014
2014
BACKGROUND To evaluate the efficacy and safety of ramucirumab (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Review
2014
Review
2014
Ramucirumab (IMC-1121B, LY3009806), a fully humanized monoclonal antibody directed against the extracellular domain of vascular… Expand
  • figure 1
  • table 1
Is this relevant?